---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-24-000049"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:37:30.777922+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports Q1 net loss $1.9M; cash $4.1M; Phase 2a IPF study interim data due Q3 2024

## Summary
- Net loss $1.9M for Q1 2024; R&D expenses $0.9M, G&A $1.0M.
- Cash and equivalents $4.1M as of March 31, 2024; public offering raised $5.5M gross in Feb 2024.
- GRI-0621 Phase 2a biomarker study in IPF: interim data Q3 2024, topline results Q4 2024.
- GRI-0803 for SLE: IND-enabling studies to complete Q3 2024; IND filing expected H2 2024.
- Expanded IP estate with Korean patent issuance and Canadian notice of allowance for NKT cell modulators.

## SEC filing metadata
- accession: 0001824293-24-000049
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000049/0001824293-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000049/val-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-24-000049
- JSON: https://secwatch.observer/filing/0001824293-24-000049.json
- Plain text: https://secwatch.observer/filing/0001824293-24-000049.txt

## Key facts
- Earnings Releases
  GRI Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $1.9 million.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss was $1.9 million
  - Result: reported results
  source text: GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000049/0001824293-24-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.